The Medicines (Advisory Bodies) Regulations 2005

Prospective

14.  In section 132 of the Act (general interpretation provisions), in subsection (1)— U.K.

(a) before the definition of “analysis”, insert the following definition—

““Advisory Body” has the meaning given to it by paragraph 1 of Schedule 1A to this Act;”,

(b) in the definition of “the Commission”, for “Medicines Commission” substitute “Commission for Human Medicines”;

(c) after the definition of “enforcement authority”, insert the following definition—

““Expert Advisory Group” means an Expert Advisory Group established under paragraph 3 or 4 of Schedule 1A to this Act;”;

(d) after the definition of “herd”, insert the following definition—

““the Homoeopathic Regulations” means the Medicines (Homoeopathic Medicinal Products for Human Use) Regulations 1994(1)”;

(e) after the definition of “manufacture”, insert the following definition—

““the Marketing Authorisation Regulations” means the Medicines for Human Use (Marketing Authorisations Etc.) Regulations 1994;”;

(f) in the definition of “the time allowed”, for “section 21(8)” substitute “section 21(12)”.

Commencement Information

I1 Sch. 1 para. 14 in force at 30.10.2005, see reg. 1(1)

(1)

S.I. 1994/105.